• Information Technology
  • Human Resources
  • Careers
  • Giving
  • Library
  • Bookstore
  • Active Living
  • Continuing Education
  • Go Dinos
  • UCalgary Maps
  • UCalgary Directory
  • Academic Calendar
My UCalgary
Webmail
D2L
ARCHIBUS
IRISS
  • Faculty of Arts
  • Cumming School of Medicine
  • Faculty of Environmental Design
  • Faculty of Graduate Studies
  • Haskayne School of Business
  • Faculty of Kinesiology
  • Faculty of Law
  • Faculty of Nursing
  • Faculty of Nursing (Qatar)
  • Schulich School of Engineering
  • Faculty of Science
  • Faculty of Social Work
  • Faculty of Veterinary Medicine
  • Werklund School of Education
  • Information TechnologiesIT
  • Human ResourcesHR
  • Careers
  • Giving
  • Library
  • Bookstore
  • Active Living
  • Continuing Education
  • Go Dinos
  • UCalgary Maps
  • UCalgary Directory
  • Academic Calendar
  • Libraries and Cultural Resources
View Item 
  •   PRISM Home
  • Alberta Gambling Research Institute
  • Alberta Gambling Research Institute
  • View Item
  •   PRISM Home
  • Alberta Gambling Research Institute
  • Alberta Gambling Research Institute
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Olanzapine in the Treatment of Schizophrenia: An Open-Label Trial in Kuwait

Thumbnail
Download
IJMHA_2005_2(2)_Fido_Al-Ansari.pdf (118.6Kb)
Download Record
Download to EndNote/RefMan (RIS)
Download to BibTex
Author
Fido, Abdullah
Al-Ansari, Essam A.
Accessioned
2010-06-22T15:33:39Z
Available
2010-06-22T15:33:39Z
Issued
2005-05-02
Other
Gambling Literature
Subject
Schizophrenia -- Treatment -- Kuwait -- Evaluation
Type
journal article
Metadata
Show full item record

Abstract
Olanzapine is a potential new "atypical" antipsychotic agent, which has been suggested to possess a superior clinical profile in the treatment of schizophrenia. The current prospective open-label trial was conducted on 10 male patients who met the DSM-IV diagnostic criteria for schizophrenia and had some residual symptoms (i.e., a global score of at least 24 on the Positive and Negative Syndrome Scale for schizophrenia, PANSS; Kay, Fiszbein, & Opler, 1987) for schizophrenia. After a washout period from previous medications (2-14 days), patients received olanzapine treatment (10-20 mg/day) dose for a 13-week period. Paired comparison of baseline and 13 weeks endpoints scores showed significant (p = .0001) improvement overtime for the negative symptoms subscale and global PANSS scores, and for the positive and general psychopathology subscale scores. Maximum efficacy of olanzapine was observed in the reduction of negative symptoms. There was no liver enzyme elevation or any other adverse serum chemistry changes resulted after treatment. There was no significant treatment-emergent EPS or dyskinetic symptoms side-effects observed. These findings support the expanded use of olanzapine in the treatment of patients with predominant negative symptoms of schizophrenia
Refereed
Yes
Copyright © Masood Zangeneh, Editor-in-Chief, International Journal of Mental Health & Addiction
 
Citation
Fido, A., & Al-Ansari, E. A. (2005). Olanzapine in the treatment of schizophrenia: An open-label trial in Kuwait. eCOMMUNITY: International Journal of Mental Health & Addiction, 2(2), 46-49.
Corporate
Kuwait University, Kuwait
Faculty
Kuwait University, Kuwait
Publisher
eCOMMUNITY: International Journal of Mental Health & Addiction
Doi
http://dx.doi.org/10.11575/PRISM/9686
Uri
http://hdl.handle.net/1880/47880
Collections
  • Alberta Gambling Research Institute

Browse

All of PRISMCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Download Results

Statistics

Most Popular ItemsStatistics by CountryMost Popular Authors

  • Email
  • SMS
  • 403.220.8895
  • Live Chat

Energize: The Campaign for Eyes High

Privacy Policy
Website feedback

University of Calgary
2500 University Drive NW
Calgary, AB T2N 1N4
CANADA

Copyright © 2017